Avantor (AVTR) Stock Price, News & Analysis

Company Overview

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.

Key Stats

• Today's Range: $20.95 to $21.47
• 50-Day Range: $19.72 to $25.06
• 52-Week Range: $19.59 to $28.00
• Volume: 10.97 million shs
• Average Volume: 6.46 million shs
• Market Capitalization: $14.44 billion
• P/E Ratio: 46.11
• Dividend Yield: N/A
• Price Target: $27.69
• Consensus Rating: Moderate Buy

Avantor Stock Analysis - MarketRank™

Avantor scored higher than 99% of companies evaluated by MarketBeat, and ranked 21st out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Avantor has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Avantor has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 15.31%

Earnings Growth

Earnings for Avantor are expected to grow by 15.31% in the coming year, from $0.98 to $1.13 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Avantor is 46.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avantor is 46.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.11.

Price to Earnings Growth Ratio

Avantor has a PEG Ratio of 2.75. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Avantor has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.96% of the outstanding shares of Avantor have been sold short.

Short Interest Ratio / Days to Cover

Avantor has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Avantor has recently decreased by 15.58%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avantor does not currently pay a dividend.

Dividend Growth

Avantor does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.2 / 5
• Environmental Score: -2.36

Percentage of Shares Shorted

3.96% of the outstanding shares of Avantor have been sold short.

Short Interest Ratio / Days to Cover

Avantor has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Avantor has recently decreased by 15.58%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.25

News Sentiment

Avantor has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Avantor this week, compared to 9 articles on an average week.

Search Interest

Only 3 people have searched for AVTR on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

4 people have added Avantor to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avantor insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.50% of the stock of Avantor is held by insiders.

Percentage Held by Institutions

95.08% of the stock of Avantor is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AVTR Stock Analysis - Frequently Asked Questions

How have AVTR shares performed this year?

Avantor's stock was trading at $22.83 at the start of the year. Since then, AVTR stock has decreased by 7.1% and is now trading at $21.21.
View the best growth stocks for 2024 here.

How were Avantor's earnings last quarter?

Avantor, Inc. (NYSE:AVTR) posted its earnings results on Friday, April, 26th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.02. The firm's quarterly revenue was down 5.6% compared to the same quarter last year.

When did Avantor IPO?

Avantor (AVTR) raised $3 billion in an IPO on Friday, May 17th 2019. The company issued 154,000,000 shares at a price of $18.00-$21.00 per share. Goldman Sachs, J.P. Morgan, BofA Merrill Lynch, Barclays and Jefferies served as the underwriters for the IPO and Credit Suisse, Deutsche Bank Securities, Evercore ISI, Guggenheim Securities, Morgan Stanley, UBS Investment Bank, Citigroup, Cowen, Piper Jaffray, RBC Capital Markets, Baird, William Blair, Janney Montgomery Scott, KeyBanc Capital Markets, PJT Partners, Raymond James, Stephens, Stifel, SunTrust Robinson Humphrey, Wells Fargo Securities and Drexel Hamilton were co-managers.

Who are Avantor's major shareholders?

Top institutional shareholders of Avantor include State Street Corp (3.29%), Janus Henderson Group PLC (2.60%), Geode Capital Management LLC (1.64%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.19%). Insiders that own company stock include Michael Stubblefield, Frederic Vanderhaegen, Gerard Brophy, James Bramwell, Christophe Couturier, Thomas A Szlosek and Steven W Eck.
View institutional ownership trends.

How do I buy shares of Avantor?

Shares of AVTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Avantor own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avantor investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Humana (HUM), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 4/26/2024
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NYSE:AVTR
• CUSIP: N/A
• CIK: 1722482
• Web: www.avantorsciences.com
• Phone: (610) 386-1700
• Fax: N/A
• Employees: 14,500
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $27.69
• High Stock Price Target: $34.00
• Low Stock Price Target: $23.00
• Potential Upside/Downside: +30.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.46
• Trailing P/E Ratio: 46.11
• Forward P/E Ratio: 21.64
• P/E Growth: 2.75
• Net Income: $321.10 million
• Net Margins: 4.54%
• Pretax Margin: 5.71%
• Return on Equity: 12.24%
• Return on Assets: 5.15%

Debt

• Debt-to-Equity Ratio: 0.84
• Current Ratio: 1.54
• Quick Ratio: 1.06

Sales & Book Value

• Annual Sales: $6.82 billion
• Price / Sales: 2.12
• Cash Flow: $1.57 per share
• Price / Cash Flow: 13.50
• Book Value: $7.77 per share
• Price / Book: 2.73

Miscellaneous

• Outstanding Shares: 680,614,000
• Free Float: 670,405,000
• Market Cap: $14.44 billion
• Optionable: Optionable
• Beta: 1.29